Contribute to a healthier future for women

Women spend 25% less of their lives in good health than men - due to decades of underinvestment in research and innovation.


NORA mobilises funding for women’s health research. You can contribute.

Endometriosis affects 1 in 10 women. We still don’t know what causes the condition.

Women are up to 50% more likely than men to die within a year of a heart attack - because of research gaps and care biases.

99% of studies on the biology of aging overlook menopause - a transition experienced by half the world’s population.

Join a community driving change in women’s health!

NORA identifies the research that matters most and makes it easy for anyone to contribute. Together - we don’t just raise funding - we build the momentum needed to accelerate change.

NORA was founded in early 2026, and we are currently establishing a Nordic Scientific Committee identifying high-impact research projects.

Our mission

To shift women’s health from a fragmented, underfunded field into a data-rich, investable sector capable of delivering both health equity and economic return.

Our research focus

01
Areas where the gap between disease burden and funding is greatest.

02
Research enabling early detection, risk factors, and a life-cycle perspective on women’s health.

03
Or targeting structural gaps, such as limitations in data collection and availability.

For decades, women’s health research has been underfunded

  • In a perfect world, the extent to which research is funded would closely correlate with disease burden - how many people are affected and how severe the condition is, or put in other words, how much it costs society.

    But in reality, funding priorities are also influenced by longstanding norms and historical biases in how different health needs are valued. 

    Across women’s health, research has continuously been underfunded relative to disease burden, resulting in significant gaps in data and scientific understanding across both female-specific conditions and those that affect women differently or disproportionately (McKinsey Health Institute, 2024). 

    These knowledge gaps have downstream consequences. They limit innovation and increase risk for investors further along the pipeline. Only around 7% of biopharma R&D is invested in women’s health, and just ~1% when excluding cancer (BMJ, 2025). When conditions are poorly understood, underdiagnosed, or lack robust datasets, it becomes significantly harder to develop effective solutions, validate outcomes, and attract capital at scale.

    In addition, existing funding structures are often siloed by specific diagnoses or medical specialties, even though evidence consistently shows the need for more cross-sector and interdisciplinary approaches as women's health conditions are often interconnected across the life course (WHO, 2021; Nature Medicine, 2023; The Lancet, 2022).

    To enable more preventive, lifecycle-based care, research cannot continue to happen in isolated silos. There is a clear need for more longitudinal datasets and integrated research frameworks that reflect how health evolves over time, rather than focusing narrowly on single conditions in isolation. The fact that this type of research is often more resource-intensive further underscores the need for new funding models.